Lead Product(s) : Eslicarbazepine Acetate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin launches Eslicarbazepine Acetate tablets in US
Details : Aptiom-Generic (eslicarbazepine acetate) is a sodium channel alpha subunit blocker, which is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
Product Name : Aptiom-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 08, 2025
Lead Product(s) : Eslicarbazepine Acetate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eslicarbazepine Acetate
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Anti-epileptogenic Effects of Eslicarbazepine Acetate
Details : Eslicarbazepine Acetate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Epilepsy, Post-Traumatic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 19, 2024
Lead Product(s) : Eslicarbazepine Acetate
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eslicarbazepine Acetate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Eisai
Deal Size : Undisclosed
Deal Type : Termination
Details : BIAL takes the lead for the marketing and distribution of Zebinix® (eslicarbazepine acetate) in Europe. Eslicarbazepine acetate is a once-daily anti-epileptic used to treat epilepsy patients with focal seizures (partial-onset seizures).
Product Name : Zebinix
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 17, 2021
Lead Product(s) : Eslicarbazepine Acetate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Eisai
Deal Size : Undisclosed
Deal Type : Termination
Lead Product(s) : Eslicarbazepine Acetate
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Trial for Zebinix (Eslicarbazepine Acetate) in Healthy Korean and Caucasian Adult
Details : Eslicarbazepine Acetate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Epilepsies, Partial.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 19, 2019
Lead Product(s) : Eslicarbazepine Acetate
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eslicarbazepine Acetate
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence of Two Different Sources of Eslicarbazepine Acetate
Details : Eslicarbazepine Acetate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Epilepsy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 17, 2017
Lead Product(s) : Eslicarbazepine Acetate
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eslicarbazepine Acetate
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eslicarbazepine Acetate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Epilepsies, Partial.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 17, 2017
Lead Product(s) : Eslicarbazepine Acetate
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eslicarbazepine Acetate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eslicarbazepine Acetate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Epilepsy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 11, 2017
Lead Product(s) : Eslicarbazepine Acetate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eslicarbazepine Acetate
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Sumitomo Pharma America
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eslicarbazepine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Epilepsy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 23, 2016
Lead Product(s) : Eslicarbazepine Acetate
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Sumitomo Pharma America
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eslicarbazepine Acetate
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers
Details : BIA 2-093 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Epilepsy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 19, 2016
Lead Product(s) : Eslicarbazepine Acetate
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eslicarbazepine Acetate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eslicarbazepine Acetate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Epilepsy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 29, 2015
Lead Product(s) : Eslicarbazepine Acetate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
